Table 1.

Selected SLCO1B1 polymorphisms

Nucleotide change	rs number	Amino acid change	In vitro function	In vivo function	Caucasians	African‐Americans	Asians
c.217T>C	rs56101265	p.F73L	Decreased		0–2	0	0
c.245T>C	rs56061388	p.V82A	Decreased		0–2	0	0
c.388A>G	rs2306283	p.N130D	Increased or unchanged	Decreased AUC pravastatin, atorvastatin	30–45	72–83	59–86
				Increased AUC pitavastatin
c.452A>G	rs2306282	p.N151S			0–3	0–2	0–4
c.463C>A	rs11045819	p.P155T	Unchanged		13–23	2–10	0–3
c.467A>G	rs72559745	p.E156G	Decreased		0–2	0	0
c.521T>C	rs4149056	p.V174A	Decreased	Increased AUC statins	8–20	1–8	8–16
				Increased risk statin‐induced myopathy
				Decreased lipid lowering efficacy
c.578T>G	rs72559746	p.L193R	Decreased		<0.3
c.733A>G	rs11045852	p.I245V			0	0–7	0
c.1007C>G	rs72559747	p.P336R	Unchanged		0		1
c.1058T>C	rs55901008	p.I353T	Decreased		0–2	0	0
c.1200C>G	rs59113707	p.F400L			0	2	0
c.1294A>G	rs56387224	p.N432D	Decreased or unchanged		0–1	0	0
c.1385A>G	rs72559748	p.D462G	Unchanged		0–1	0	0
c.1463G>C	rs59502379	p.G488A	Decreased		0	3–9	0
c.1495A>G	rs74064213	p.I499V				6
c.1929A>C	rs34671512	p.L643F	Unchanged		3–9	5–13	0–1
c.1964A>G	rs56199088	p.D655G	Decreased		0–2	0	0
c.2000A>G	rs55737008	p.E667G	Unchanged		0–2	0–34	0